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Objectives
To analyze risk management when occurred hepatone-
phritis cases related to Artemisinin-based Combinations
Therapy.
Methods
A technical committee of management of hepatonephritis
cases has been set up by the health ministry. The terms of
references were: 1) state of knowledges on the subject
from the pharmacovigilance database of Côte-d’Ivoire; 2)
Carrying out of an investigation in public and private hos-
pitals; 3) start -up a plan of communication for the health
professionals and population.
Results
States of knowledges: for 10 years, serious Adverse Drug
reactions have been notified (57%), like black fever,
hepatonephritis and serious hepatitis cases related to any
antimalarial monotherapies : amodiaquin, artemisinin
derivatives and quinine. Retrospective study: we collected
100 files. The principal damage was hepatic (63%), hepa-
torenal (26%) and hematologic (19%). Antimalarial drugs
implicated were: quinine (30,4%), artemether-lumefantine
(21,4%) and artesunate-sulfamethopyrazine (13,6%).
Prospective study: We have analyzed 25 cases over 3
months of investigation.
Conclusion
Start-up of a plan of communication: we drafted and sent
an alarm note and recommendations of good use of anti-
marial combinotherapies to prescribers and dispensers.
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